National Comprehensive Cancer Network
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of National Comprehensive Cancer Network
Names of Lobbyists
Most Frequently Disclosed Lobbying Issues
- Health Issues
RegulationsMentioned in 17 dockets; Submitted to 1 docket
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "National Comprehensive Cancer Network" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for National Comprehensive Cancer Network
Mentions in Document Text
View all mentions data for National Comprehensive Cancer Network
- Toggle 10 CMS Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule, DME Face-to-Face Encounters, Elimination of the Requirement for Termination of Non-Random Prepayment Complex Medical Review and Other Revisions to Part B for CY 2013 (CMS-1590-P) 2012
- Toggle 6 FDA Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories; Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs); Availability 2011
- Toggle 2 CMS Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Fiscal Year 2013 Rates; Hospitals’ Resident Caps for Graduate Medical Education Payment Purposes; Quality Reporting Requirements for Specific Providers and for Ambulatory Surgical Centers 2012
- Toggle 1 FDA InSightec, Inc., Premarket Approval of InSightec ExAblate® System P110039, Approved 10/18/12 2012
- Toggle 1 CMS Medicare Program: Hospital Value-Based Purchasing Program 2011
- Toggle 1 CMS Electronic Health Record Incentive Program – Stage 2 "Meaningful Use" 2012
- Toggle 1 FDA Abbott Molecular, Inc., Premarket Approval of Vysis ALK Break Apart FISH Probe Kit; Vysis Paraffin Pretreatment IV & Post Hybridization Wash Buffer Kit; ProbeChek ALK Negative Control Slides; and ProbeChek ALK Positive Control Slides P110012, Approved 8/26/11 2011
- Toggle 1 CMS Exchanges Part II--Standards Related to Essential Health Benefits; Health Insurance Issuer and Exchange Responsibilities with Respect to Actuarial Value, Quality, and Accreditation CMS-9980-P 2012
- Toggle 1 IRS Summary of Benefits and Coverage and Uniform Glossary 2011
- Toggle 1 FDA Medical Devices; Immunology and Microbiology Devices; Classification of Ovarian Adnexal Mass Assessment Score Test System-CLOSED 2011